AI assistant
ELI LILLY & Co — Director's Dealing 2019
May 7, 2019
29745_dirs_2019-05-07_c6241687-769c-4382-a7af-dab29902cb61.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LILLY ELI & CO (LLY)
CIK: 0000059478
Period of Report: 2019-05-03
Reporting Person: Shaw Christi (SVP and Pres., Lilly Bio-Meds)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-05-03 | Common Stock | S | 7077 | $117.08 | Disposed | 500 | Direct |
| 2019-05-03 | Common Stock | S | 500 | $117.99 | Disposed | 0 | Direct |
Footnotes
F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 20, 2019.
F2: This transaction was executed in multiple trades at prices ranging from $116.68 to $117.46. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $117.82 to $118.15. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.